01:10 PM EDT, 08/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We maintain our target price of $14, 5.8x our 2026 EPS estimate, a discount to IART's historical forward average due to compliance issues. We cut our 2025 EPS estimate by $0.02 to $2.21 and 2026's by $0.30 from $2.72 Total revenues of $415.6M declined 0.6% Y/Y but exceeded consensus expectations by 5%. Integra Skin was a bright spot, returning to normal revenue levels and achieving its highest-ever production rate for this key product. IART reaffirmed its 2025 EPS guidance range of $2.19-$2.29 despite ongoing headwinds. EBITDA declined to $71.2M (17.1% of revenue) from $83.8M (20.0%) as gross margin dropped 450 bps to 60.7% due to ongoing compliance-related costs, supply chain challenges, and Compliance Master Plan implementation expenses. The company is being proactive and established a Program Management Office and Supply Chain Control Tower to drive operational improvements. We expect underlying demand for neurosurgery and tissue technology to remain strong in 2H 2025.